Cough Assist Devices Market Size & Share 2026-2035

Cough Assist Devices Market Size

The global cough assist devices market was valued at USD 262.3 million in 2025, is projected to reach USD 281.5 million in 2026, and is expected to attain USD 505.1 million by 2035, expanding at a CAGR of 6.7% from 2026 to 2035.

The 8.8% historic CAGR recorded from 2022 to 2024 reflected accelerating diagnosis of neuromuscular conditions, wider use of home respiratory equipment, and demand for secretion-management pathways following acute respiratory episodes.

Mechanical insufflation-exsufflation (MI-E) is the market's central therapy mechanism. It alternates positive and negative airway pressure to create expiratory flow when a patient cannot produce an effective cough independently. Clinical practice literature identifies cough-flow impairment as a material secretion-retention risk in people with neuromuscular weakness and spinal cord injury, making mechanically assisted cough particularly relevant where manual techniques no longer provide adequate airway clearance, ^{[1]SCIRE Project, Cough Assist and Secretion Removal evidence summary, updated 2025, scireproject.com}. This clinical requirement differentiates cough assist devices from general respiratory wellness equipment: purchasing decisions depend on diagnosis, caregiver capability, interface tolerance, and the reimbursement route available after hospital discharge.

Demand is anchored most directly in ALS, spinal muscular atrophy, Duchenne muscular dystrophy, spinal cord injury, and other disorders associated with respiratory muscle weakness. ALS prevalence is expected to rise as populations age; a global projection estimated that the number of people living with ALS could increase from 222,801 in 2015 to 376,674 by 2040 ^{[2]Nature Communications, Projected increase in amyotrophic lateral sclerosis from 2015 to 2040, 2016, nature.com}. Chronic respiratory disease also broadens the clinically relevant population, although not every patient with COPD or bronchiectasis is an MI-E candidate. COPD caused 3.4 million deaths in 2023 and remains a major global respiratory disease burden.

The commercial ecosystem includes MI-E manufacturers, multi-function respiratory-platform providers, home healthcare operators, DME suppliers, respiratory therapists, and accessory distributors. Philips held an 18.5% share of global revenue in 2024. Philips, Baxter, Air Liquide Healthcare, ICU Medical, and Ventec Life Systems collectively accounted for approximately 55% of market revenue, while specialist suppliers compete through device functionality, regional regulatory access, clinical support, and distribution coverage.

Commercial value is increasingly determined by the ability to convert clinical need into a reimbursed home-care episode. North America's established DME infrastructure supports current revenue, whereas Asia Pacific's higher growth rate depends more heavily on regulatory registrations, specialist distribution, and the gradual expansion of coverage pathways. Manufacturers able to combine an effective device with training, remote-data capability, and dependable service support are better positioned than vendors competing on hardware specification alone.

Key Drivers

Rising prevalence of chronic respiratory diseases and neuromuscular disorders

Cough assist demand rises when a patient's disease progression compromises the ability to mobilize secretions independently. Neurological conditions affected more than 3 billion people globally in 2021, according to the World Health Organization, underscoring the scale of the broader neurological disease burden from which respiratory-muscle impairment cases emerge ^{[3]World Health Organization, Global Status Report on Neurology, 2023, iris.who.int}. The addressable market is narrower than this population, but it expands when diagnosis, respiratory monitoring, and referral to specialist care improve.

Evidence from an ALS multicenter cohort illustrates the therapy's embedded role in clinical management. Among clinically indicated patients, 75.9% received MI-E therapy, and daily use was reported by 78.4% of those receiving treatment ^{[4]Scientific Reports, Provision, cough efficacy and treatment satisfaction of mechanical insufflation-exsufflation in a large multicenter cohort of patients with ALS, 2025, nature.com}. Such utilization supports recurring demand for interfaces, circuits, replacement components, clinical follow-up, and training rather than a one-time equipment transaction.

Aging global population with weakened respiratory muscles

Population aging increases exposure to both neuromuscular disease and declining respiratory reserve. The World Health Organization projects that the number of people aged 60 years or older will grow from 1.1 billion in 2023 to 1.4 billion by 2030. Age-related loss of muscle strength, reduced chest-wall compliance, and a higher incidence of progressive neurological conditions can make secretion management more difficult during respiratory infection, post-operative recovery, or disease exacerbation.

Japan illustrates the operational dimension of aging. People aged 65 years or older accounted for 29.1% of its population in 2023, while the average age of caregivers in its home respiratory-care context was 68 years. This demographic combination favors equipment that reduces the physical and technical burden on family caregivers, particularly devices with stored therapy programs, clearer interfaces, and synchronization features.

Shift toward home healthcare and long-term care settings

Home respiratory care is the principal channel through which a hospital-initiated MI-E regimen becomes a sustained therapy program. In the United States, Medicare policy recognizes mechanical in-exsufflation equipment and related accessories under its DME framework when coverage criteria are met. The policy structure creates a pathway for home deployment, but it also makes clinical documentation and supplier compliance central to market access.

France provides a contrasting example of a national assessment-based model. The Haute Autorité de Santé has supported continued reimbursement for assisted-cough devices used by people with neurological and neuromuscular conditions at home. In Spain, Air Liquide's home respiratory-care contract with the Community of Madrid incorporates digital monitoring and care coordination, showing how large providers are competing on service delivery and patient management rather than equipment supply alone.

Continuous technological advancements in portable, automated, and connected devices

Automatic cough assist devices held 72.3% of market revenue in 2025 and are projected to grow at a CAGR of 6.9% through 2035. Their share reflects a practical advantage in home care: programmed therapy sequences and monitoring features reduce reliance on caregivers manually timing pressure cycles.

Integration is becoming a meaningful product differentiator. Ventec's VOCSN platform combines ventilation, oxygen, cough, suction, and nebulization in one portable system, reducing the number of devices and circuit changes required for patients using multiple therapies. ABM Respiratory Care's BiWaze Cough uses separate inspiratory and expiratory pathways and includes pressure support during the pause interval, illustrating the shift toward devices designed around airway management, infection control, and caregiver workflow rather than pressure delivery alone.

Connectivity is also becoming commercially relevant. Breas integrated its EveryWare cloud capability with Encore Healthcare's Nexus respiratory-management platform in 2025, enabling care teams to view respiratory-therapy information through a consolidated workflow. Such systems may strengthen supplier relevance where home-care providers require evidence of adherence, therapy delivery, and clinical follow-up.

Key Restraints

High purchase price of devices for many healthcare providers and patients

Automatic MI-E systems require a higher initial outlay than manual alternatives, and the price burden is most acute where devices are not reimbursed. Hospitals in lower-resource settings may prioritize ventilators, monitoring equipment, and acute-care infrastructure over specialized airway-clearance systems. This can preserve demand for lower-cost manual devices, but it also increases training requirements and may limit use outside specialist settings.

For DME providers, device economics are shaped by more than the equipment price. Documentation, inventory management, patient onboarding, servicing, and accessory supply all affect the profitability of a reimbursed placement. Consequently, a clinically useful device may still face restricted access if the supplier cannot sustain the administrative and service burden attached to home deployment.

Limited or inconsistent reimbursement policies across regions

Coverage remains uneven across countries and payers. U.S. Medicare offers a defined DME route for eligible patients, whereas access elsewhere may depend on a country-specific reimbursement decision, hospital budget, private insurer policy, or direct payment. The consequence is a fragmented market in which identical clinical need can result in materially different device access.

Regulatory requirements can compound this access gap. The European Union's Medical Device Regulation requires manufacturers to meet updated obligations for medical-device market access, including strengthened clinical and technical documentation requirements. For smaller manufacturers, the cost and timing of compliance can delay launches or constrain geographic expansion, particularly when reimbursement approval must be pursued separately after regulatory clearance.

The restraint is therefore not simply device cost. It is the absence of a coordinated pathway linking diagnosis, prescription, financing, delivery, caregiver training, and follow-up. Companies that address several of these steps through DME partnerships or managed-care programs can expand practical access without waiting for a universal reimbursement standard.

Cough Assist Devices Market Segment Analysis

By Product Type

Automatic cough assist devices held 72.3% of global revenue in 2025 and are projected to exceed USD 370.1 million by 2035, expanding at a CAGR of 6.9%. Their advantage lies in repeatable pressure delivery, programmable settings, synchronization capability, and easier use by non-specialist caregivers. These features are especially relevant as MI-E therapy moves from hospital respiratory departments to private homes and long-term care settings.

Manual cough assist devices are projected to reach USD 135.1 million by 2035 at a CAGR of 6.3%. They retain a role where purchase budgets are constrained, where treatment is clinician-supervised, or where providers prioritize simple equipment with lower acquisition costs. The segment's slower growth reflects the increasing preference for automated therapy in settings where caregiver time and treatment consistency carry greater weight.

By Choice of Delivery

Mouthpiece delivery accounted for 45.5% of market revenue in 2025. It remains well suited to patients who can independently maintain an effective oral seal and manage repeated therapy sessions without continuous caregiver assistance. This makes it particularly relevant for ambulatory patients and for individuals with earlier-stage neuromuscular impairment.

Face masks are forecast to reach USD 186.2 million by 2035 and grow at a CAGR of 7.2%. The segment benefits from applicability among pediatric patients, individuals with bulbar weakness, and patients unable to manage a mouthpiece consistently. Growth therefore reflects disease progression and care dependency as much as interface preference.

Adapters are projected to reach USD 93.7 million by 2035 at a CAGR of 6.3%. They are used when MI-E is delivered through tracheostomy or endotracheal interfaces, linking cough assistance with ICU, long-term acute care, and invasive ventilation pathways. ABM Respiratory Care received expanded FDA clearance in 2024 for in-line ventilator use of BiWaze Clear, demonstrating continued development of airway-clearance systems for acute-care environments ^{[5]ABM Respiratory Care, ABM Respiratory Care Announces an Expanded Indication for BiWaze Clear, April 9, 2024, abmrc.com}.

By End Use

Hospitals accounted for 40.9% of revenue in 2025. They remain the principal site for therapy initiation, patient assessment, pressure titration, and management of high-acuity respiratory cases. Hospital adoption also influences downstream home demand because successful inpatient initiation can establish a prescribed treatment routine before discharge.

Home care settings are projected to reach USD 196.1 million by 2035 at a CAGR of 7.0%. Their growth reflects DME reimbursement in the United States, national support in selected European markets, and the availability of more portable, caregiver-operable equipment. The segment has particular strategic value because multi-year therapy creates demand for service, interfaces, and replacement accessories.

Other end users, including long-term acute care facilities, skilled nursing settings, hospice programs, and outpatient neuromuscular clinics, are projected to reach USD 101.2 million by 2035 at a CAGR of 6.0%. These settings connect hospital discharge with independent home management and require devices that can accommodate varying levels of clinician supervision.

Face masks are positioned to outgrow mouthpieces because the patient population includes people with advancing weakness and more dependent care needs. This changes design priorities: fit, comfort, leakage management, and caregiver application may matter as much as maximum pressure specification. Adapter demand, by contrast, remains more closely tied to institutional and invasive-ventilation settings, preserving a distinct product and channel requirement.

Cough Assist Devices Market Regional Analysis

North America

North America generated USD 95.8 million in 2025, representing 36.5% of global revenue, and is projected to reach USD 169.9 million by 2035 at a CAGR of 5.83%. Its market position is supported by established DME reimbursement, specialist respiratory-care infrastructure, and a large installed base of home-care providers. The United States accounted for USD 89.6 million in 2025 and is projected to reach USD 157.4 million by 2035 at a CAGR of 5.74%. Canada is expected to rise from USD 6.3 million in 2025 to USD 12.4 million in 2035 at a CAGR of 7.05%.

The U.S. market has been affected by Philips' decision to discontinue CoughAssist product sales and shipments, creating an opening for alternative suppliers serving DME channels and existing patients. Breas obtained FDA clearance for Clearo in May 2025, while ABM Respiratory Care launched BiWaze Cough across Canada with McArthur Medical Sales in August 2025, ^{[6]ABM Respiratory Care, ABM Respiratory Care and McArthur Medical Sales Announce Nationwide Launch of BiWaze Cough in Canada, August 14, 2025, abmrc.com}.

Europe

Europe is projected to increase from USD 74.8 million in 2025 to USD 139.9 million in 2035, at a CAGR of 6.41%. Germany, the UK, France, Spain, Italy, and the Netherlands are the key country markets. Reimbursement mechanisms, national respiratory-care systems, and EU MDR compliance shape competitive access across the region.

The UK's clinical coverage criteria for MI-E place emphasis on neuromuscular disease and cough-flow impairment, while France maintains a defined assessment and reimbursement framework for assisted-cough devices ^{[7]Anthem/Wellpoint, CG-DME-54 Mechanical Insufflation-Exsufflation Devices, Medical Policy, anthem.com}. Germany is important for integrated home-care models: Air Liquide acquired two German outpatient intensive-care providers in May 2025, extending its managed-care reach among patients with chronic respiratory insufficiency and neuromuscular conditions.

Asia Pacific

Asia Pacific is forecast to grow from USD 65.6 million in 2025 to USD 141.5 million in 2035, recording the fastest regional CAGR of 7.93%. China, Japan, India, Australia, and South Korea form the core regional markets. Growth reflects aging populations, expanding respiratory-care capacity, and rising interest in home-based chronic disease management, although regulatory registration and reimbursement remain uneven.

Japan's demographic profile supports demand for caregiver-friendly respiratory equipment, while China's size and evolving care infrastructure create a substantial longer-term opportunity. India's demand potential is influenced by large respiratory disease burdens and uneven access to specialist equipment. South Korea-based Seoil Pacific expanded its regional regulatory presence when its Comfort Cough II was entered on Australia's ARTG in October 2025.

Latin America

Latin America is projected to rise from USD 14.6 million in 2025 to USD 30.5 million in 2035 at a CAGR of 7.56%. Brazil and Mexico lead regional demand, with Argentina representing a smaller but relevant market. Hospital procurement remains the dominant channel because structured reimbursement for home MI-E is limited across much of the region.

Regional growth will depend on the expansion of tertiary respiratory-care capability, private insurance coverage, and specialist distribution beyond major urban centers. Providers that can support clinician training and post-installation servicing are likely to have an advantage because device adoption is constrained by operational capacity as well as purchasing budgets.

Middle East and Africa

The Middle East and Africa market is expected to increase from USD 11.5 million in 2025 to USD 23.3 million in 2035, at a CAGR of 7.23%. South Africa, Saudi Arabia, and the UAE are the principal markets. Demand is concentrated in private healthcare systems, specialist hospitals, and critical-care settings because broad home-care reimbursement remains limited.

Saudi Arabia and the UAE offer the most immediate opportunities for advanced respiratory-care equipment as investment in specialized hospital services continues. South Africa provides a comparatively developed private-care channel, but broader regional expansion remains dependent on distributor capability, clinical training, and selective extension of insurance benefits for durable respiratory equipment.

Asia Pacific's 7.93% CAGR points to a different opportunity: high potential but a more demanding route to commercialization. Regulatory approvals, local distribution, and clinician education must be established before population scale converts into revenue. Latin America and MEA offer similarly attractive growth rates from smaller bases, but their commercial model is likely to remain hospital-centered until reimbursement and home-care infrastructure develop more consistently.

Cough Assist Devices Market Share & Competitive Landscape

The market is moderately concentrated. Philips held the largest individual share at 18.5% in 2024, while Philips, Baxter, Air Liquide Healthcare, ICU Medical, and Ventec Life Systems together represented approximately 55% of revenue. The remaining market is distributed among specialized manufacturers, respiratory-care suppliers, diagnostics participants, and regional distributors.

Philips retains relevance through its installed CoughAssist base, even after discontinuing new CoughAssist sales and shipments. Baxter participates through its airway-clearance portfolio, including the Synclara Cough System and The Vest platform. Baxter launched The Vest Advanced Pulmonary Experience System in September 2024 after FDA clearance, reinforcing its position across the broader airway-clearance category ^{[8]Baxter International, Baxter Launches Next Generation of The Vest System for Airway Clearance, September 26, 2024, investor.baxter.com}.

Air Liquide Healthcare combines equipment distribution with a managed home-care delivery model. Its acquisitions in Belgium, the Netherlands, and Germany broaden the patient-service infrastructure through which respiratory therapies can be deployed ^{[9]Air Liquide, Air Liquide strengthens its Home Healthcare activity with an acquisition in Belgium and the Netherlands, April 9, 2024, airliquide.com}. ICU Medical participates through its acapella OPEP portfolio and introduced the MyAcapella digital coaching application with VisionHealth in May 2025. Ventec Life Systems differentiates through VOCSN, an integrated multi-therapy respiratory platform.

Breas Medical, ABM Respiratory Care, Dima Italia, and Seoil Pacific compete through MI-E specialization, regulatory expansion, and device functionality. Breas' Clearo clearance supports a U.S. alternative for the CoughAssist installed base. ABM Respiratory Care is building product and distribution reach through BiWaze Cough and BiWaze Clear, while Dima Italia supplies the Pegaso Cough platform. Seoil Pacific's Comfort Cough II extends the specialist competitive set across Asia Pacific and Australia.

PhysioAssist (Simeox), operating through Simeox technology, participates in airway clearance through variable oscillating-pressure therapy. Inogen announced FDA clearance for the SIMEOX 200 in December 2024 following its acquisition of PhysioAssist. PARI contributes complementary PEP and nebulization capabilities, while Vitalograph occupies a diagnostic role through pulmonary function and oscillometry platforms. Vitalograph acquired Morgan Scientific in 2024 and partnered with Thorasys to launch the tremoflo C2 oscillometer in the United States in 2025,. West Care Medical supports Canadian hospital and home-care access as a specialty respiratory distributor.

Competitive advantage is increasingly shaped by the ability to support an entire respiratory-care workflow. Hardware performance remains essential, but market access also depends on clearance status, reimbursement documentation support, home-care partnerships, clinical training, connected-data capability, and availability of interfaces and replacement accessories.

Recent Industry Developments

• May 15, 2025 - ICU Medical and VisionHealth launched MyAcapella. ICU Medical and VisionHealth launched MyAcapella, a digital coaching application for OPEP therapy that provides guided instruction, reminders, education, and adherence support.
• May 16, 2025 - Breas Medical received FDA clearance for Clearo. The FDA cleared Breas Medical's Clearo MI-E device for adult and pediatric use in invasive and non-invasive applications.